Russian President Vladimir Putin said on Wednesday he has taken an experimental nasal vaccine against the coronavirus, three days after he received his booster shot, as Russia faces its worst surge of infections and deaths since the pandemic began. Putin was vaccinated with Sputnik V, Russia’s domestically developed COVID-19 vaccine, in the spring.
On Sunday, he said he received a booster shot of Sputnik Light, the one-dose version of the jab, and said he wanted to take part in testing the nasal version of Sputnik V.
Denis Logunov, deputy director of Russia’s state-funded Gamaleya Center that developed Sputnik V, told Putin on Sunday the nasal vaccine is yet to go through clinical studies and is currently being tested “off-label mostly” — on the center’s staff members.
In accordance with established scientific protocols, the vaccine will need to go through several trial phases, including those involving thousands of people, to establish that it is safe and effective to use.
Last month, Russia’s Health Ministry gave a regulatory go-ahead to early trials of the nasal form of Sputnik V among 500 volunteers, but it was not immediately clear whether it has already started.
Putin told a government meeting Wednesday that “exactly six months after vaccination my titers of protective (antibodies) have dropped, and specialists recommended the procedure of revaccination, which I did.” He said he didn’t experience any unpleasant effects after taking the nasal vaccine.
In recent weeks, Russia has been swept by its highest ever COVID-19 surge, with officials regularly registering record-high numbers of new infections and deaths.
The surge came amid low vaccination rates and lax public attitudes toward taking precautions. Fewer than 40 per cent of Russia’s nearly 146 million people have been fully vaccinated, even though the country approved a domestically developed COVID-19 vaccine months before most of the world.
Russians are currently offered four domestically developed vaccines, with Sputnik V and Sputnik Light dominating the market.
Data on efficacy of two other ones, EpiVacCorona and CoviVac, is yet to be released; just like Sputnik V, these two shots have been given regulatory approval before completing late-stage trials necessary to establish their effectiveness in preventing disease.
Russia’s Health Ministry is expected to approve a version of Sputnik V for teenagers aged 12 to 17 on Wednesday, Deputy Prime Minister Tatyana Golikova told Putin during the government meeting.
According to the Russia’s state registry of clinical trials, the jab, which is in essence a smaller dose of Sputnik V, was being tested on more than 3,600 volunteers. No data on its efficacy has been released yet. Russia’s state coronavirus task force reported 33,558 new infections on Wednesday and 1,240 deaths.
Golikova called the daily mortality numbers “dramatic,” noting at the same time that contagions in the country have taken a downward trend.
In total, the task force has reported over 9.4 million confirmed infections and more than 267,000 COVID-19 deaths, by far the highest death toll in Europe. Some experts believe the true figure is even higher.
Reports by Russia’s statistical service, Rosstat, that tally coronavirus-linked deaths retroactively, reveal much higher mortality. They say 462,000 people with COVID-19 died between April 2020 and September of this year.
Russian officials have said the task force only includes deaths for which COVID-19 was the main cause, and uses data from medical facilities. Rosstat uses wider criteria for counting virus-related deaths and takes its numbers from civil registry offices where registering a death is finalised.
- COVID case rates hit new high for England, study finds - April 7, 2022
- Govt’s focus on affordable healthcare ensured significant savings for poor, middle class: PM Modi - April 7, 2022
- SRL Diagnostics and Skye Air Mobility collaborate to transport pathology samples using drone logistics - April 6, 2022
- Healthineers sets up new production line of CT scanners in Bengaluru under PLI scheme - April 6, 2022
- Lupin inks licensing pact with Alvion to market drugs in Southeast Asia - April 6, 2022
- Yoga Mahotsav: Ayush Ministry to organise event to demonstrate common yoga on World Health Day - April 6, 2022
- LordsMed forays into the medtech space with launch of health ATMs ‘Lords Sehat’ - April 5, 2022
- ‘Friendly viruses’ can be the next big thing in the history of medical research and more - April 5, 2022
- No setback to Bharat Biotech even as WHO suspends Covaxin UN supply: Sources - April 4, 2022
- Govt panel recommends Serum’s Covovax dose for kids aged 12 and above - April 4, 2022